This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Coronavirus Woes Affect Gilead's (GILD) Q3 Earnings?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on experimental coronavirus treatment, when Gilead (GILD) reports third-quarter 2020 results.
Seagen Posts Upbeat Top-Line Data From EV-201 Study on Padcev
by Zacks Equity Research
Seagen (SGEN) and partner Astellas Pharma post favorable top-line results from the second cohort of the phase II EV-201 study on Padcev to treat advanced or metastatic urothelial cancer. Stock rises.
Immunomedics' Trodelvy Gets Orphan Drug Tag for Glioblastoma
by Zacks Equity Research
Immunomedics' (IMMU) lead product candidate, Trodelvy, gets FDA orphan drug status for the treatment of adult and pediatric patients with glioblastoma.
Axovant's Gene Therapy Gets Rare Pediatric Disease Status
by Zacks Equity Research
The FDA bestows a Rare Pediatric Disease status on Axovant's (AXGT) gene therapy candidate AXO-AAV-GM1, which is being developed for the treatment of GM1 gangliosidosis. Stock appreciates.
Pharma M&As Pick Up as Bristol-Myers Offers to Buy MyoKardia
by Kinjel Shah
After a relatively dull first half of 2020, M&A activity in the drug and biotech sector seems to be picking up in the second half of 2020.
Immunomedics Releases Trodelvy Data From Cancer Studies
by Zacks Equity Research
Immunomedics (IMMU) releases data from different cancer studies on its lead drug, Trodelvy.
Healthcare ETFs, Stocks That Gained Double Digits Last Week
by Sweta Killa
The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.
Williams-Sonoma, Tanger Factory Outlet, Gilead Sciences, Immunomedics and Jounce Therapeutics highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Williams-Sonoma, Tanger Factory Outlet, Gilead Sciences, Immunomedics and Jounce Therapeutics highlighted as Zacks Bull and Bear of the Day
Gilead's Oncology Drug Gets Breakthrough Therapy Designation
by Zacks Equity Research
Gilead's (GILD) magrolimab obtains Breakthrough Therapy designation in the United States for the treatment of newly-diagnosed myelodysplastic syndrome (MDS).
M&A ETFs Sizzling on Recent Deal Activities
by Sweta Killa
After tumbling to the lowest level in more than a decade in the second quarter, global M&A activity gathered steam in September following the flurry of latest deal activities.
Biotech Stock Roundup: GILD to Buy IMMU, SGEN Collaborates With Merck & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?
by Zacks Equity Research
Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.
Biotech ETFs Soars on Gilead-Immunomedics Deal
by Sweta Killa
The acquisition will expand Gilead's portfolio of treatments for various types of cancer.
Stock Market News for Sep 15, 2020
by Zacks Equity Research
U.S. stock markets closed higher on Monday reversing some of the losses of the last week.
ETFs in Focus on Tug of War Between Bulls and Bears
by Sweta Killa
Both bull and bear ETFs are showing immense potential as abrupt changes in sentiments have raised the appeal for these products.
M&A Activities Intensify in Pharma Industry
by Zacks Equity Research
M&A Activities Intensify in Pharma Industry.
No Econ Data, but Big Biopharma News
by Mark Vickery
Merck, Gilead and Lilly make progress on an otherwise slow news day.
Gilead to Buy Oncology Company Immunomedics for $21 Billion
by Zacks Equity Research
Gilead (GILD) looks to fortify its oncology portfolio with the acquisition of Immunomedics and the addition of Trodelvy to its portfolio.
Immunomedics to be Acquired by Gilead for About 21 Billion
by Zacks Equity Research
Immunomedics Inc. (IMMU) will be acquired by Gilead (GILD) for about $21 billion.
Why Is Immunomedics (IMMU) Down 6.7% Since Last Earnings Report?
by Zacks Equity Research
Immunomedics (IMMU) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunomedics (IMMU) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Immunomedics (IMMU) delivered earnings and revenue surprises of 11.76% and -19.08%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Advanced Micro Devices, Under Armour, Immunomedics, GenMark and Co-Diagnostics highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Advanced Micro Devices, Under Armour, Immunomedics, GenMark and Co-Diagnostics highlighted as Zacks Bull and Bear of the Day
3 Inexpensive MedTech Gainers of 2H20 Beyond TMO and RMD
by Zacks Equity Research
Here we look at three cheap MedTech stocks that investors can take a look at apart from giants like Thermo Fisher and ResMed that are expensive.
Immunomedics Extends Deal With Roche for Two New Studies
by Zacks Equity Research
Immunomedics (IMMU) extends agreement with Roche to evaluate the combination of Trodelvy and Tecentriq in patients with mUC and mNSCLC.
Amgen (AMGN) Invests Further in China-Based Oncology Partner
by Zacks Equity Research
Amgen (AMGN) announces additional investment of approximately $421 million in BeiGene. The companies have a collaboration for oncology products signed in 2019.